Navigation Links
Genelabs Technologies Announces Completion of $23.7 Million Registered Direct Financing
Date:10/1/2007

Funds to Support Ongoing HCV Drug Discovery Projects

REDWOOD CITY, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) announced today that it has completed its previously announced sale of approximately 12.9 million shares of its common stock and warrants to purchase approximately 2.6 million shares of its common stock for gross proceeds of approximately $23.7 million. Genelabs sold the shares and warrants for $1.84 per unit (each unit consisting of one share and a warrant to purchase 0.20 shares of common stock). The exercise price of the warrants is $2.08 per share. The warrants will be exercisable at any time prior to the fifth anniversary of October 1, 2007. Genelabs plans to use the proceeds from this financing to support its ongoing hepatitis C virus (HCV) drug discovery programs and for general corporate purposes. The proceeds will not be used to fund a new phase III clinical trial of Prestara. Deutsche Bank Securities Inc. acted as exclusive placement agent in the transaction.

A shelf registration statement relating to these securities (File No. 333-145497) has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offer of these securities will be solely by means of a prospectus included in the registration statement and any prospectus supplement that may be issued with respect to such offering. Copies of the final prospectus, i
'/>"/>

SOURCE Genelabs Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Researchers Develop Technologies to Devour Food Pathogens
2. Researchers Study Safety of Assisted Reproductive Technologies
3. India to Propose Global Fund for Clean Energy Technologies
4. PM announces a new health care order for India
5. Ramdoss Announces Introduction of RCH-II
6. Britain Announces Third Transfusion Related Mad Cow Case
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. PowderMed Announces Needle-Less Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)... hospitals to reconsider or defer purchases of ima...Group , , WALTHAM, Mass., Jan. 8 /PRNewswire/ -... US Markets for PACS, RIS, and CVIS 2009 report,... facilities will significantly affect the markets ...ACS), radiology information systems (RIS), and car...
(Date:1/8/2009)...avid Bruce Joins as President and Chief Executive ...re-FirstCall/ -- Patient Safety Technologies (OTC ...ruce has joined the company as its President and C...d of Directors. Bill Adams, the company,s former C...he company as a consultant. , , David brings a ...
(Date:1/8/2009)... response to the growing consumer demand for weigh...g these procedures has also skyrocketed, enabling ...lecting a board-certified surgeon who is a member ...) helps ensure safe, permanent weight loss options...09 -- Due to the increasing popularity of weight l...
(Date:1/8/2009)...ur scientific studies have now reported that expos...crease the likelihood of sleep disturbance. The ca...ll as those from other electrical appliances and h...amaging free radicals in the cerebrospinal fluid (...the sleep-controlling hormone melatonin. , ...
Breaking Medicine News(10 mins):Health News:Budgetary Constraints on Health Care Facilities to Affect PACS, RIS, and CVIS Markets 2Health News:Patient Safety Technologies Announces Expansion of Senior Management Team 2Health News:Choosing a Highly-Trained Bariatric Surgeon Crucial as Surgical Weight Loss Procedures Rise and Less-Qualified Doctors Flood the Market 2Health News:Choosing a Highly-Trained Bariatric Surgeon Crucial as Surgical Weight Loss Procedures Rise and Less-Qualified Doctors Flood the Market 3Health News:Welsh Laboratory Discovers Natural Antidote for Sleep Disturbance Caused by Cell Phones; Don't Disturb Me! Asphalia for Natural Sleep 2Health News:Welsh Laboratory Discovers Natural Antidote for Sleep Disturbance Caused by Cell Phones; Don't Disturb Me! Asphalia for Natural Sleep 3
...hat decrease in the fine particulate air pollution.... This drop in mortality rates was specifically ob...ase, according to Dr. Francine Laden, from Harvard...n a statement. Several epidemiologic studies have ...
...n the opinion of parents’ when compared to rugby-c...esearch has pointed out that Australian Football a...l other types of football. // The Aussie code see...juries, the second place being occupied by league ...
...a binge drinker, who is over the board regularly, ... worthwhile to kick the tendency. // Medical exper...that cirrhosis, a disease of the liver is not far ... waiting to explode. Infact, figures show that t...
...ology and Community Health reports that deaths fr...duced by almost half since the Mid 1980s. // This...duction in smoking, the study reveals. Deaths fro..., dropped by almost 47%, between 1985 and 2000, am...
Other Medicine News:Health News:Bottleneck: High on Spirits Can Cause A Dispirited Liver, Leading To Cirrhosis! 2
(Date:1/7/2009)...re/ -- Scientists have identified mutations in a g...hildren with acute lymphoblastic leukemia (ALL). A...rch is needed to determine how changes in the gene...apse, the findings are likely to provide the basis... treatment failure. By using a molecular test to i...
(Date:1/7/2009)...sed On Osteotech,s Proprietary Human Collagen Tech...iling Anticipated in Third Quarter 2009 , , EA...Osteotech, Inc. (Nasdaq: OSTE ), a leader in the...ive healing, announced today that it has initiated...Regeneration Matrix. The first five patients in th...
(Date:1/6/2009)...prior U.S., U.K. and China Trials , , SAN DIEGO...I), a development stage company targeting liver di...n for a randomized, controlled, multi-center, Phas...eal Liver Assist Device (ELAD) as a treatment for ...e protocols. The study is open for enrollment at s...
(Date:1/6/2009)... The Michael J. Fox Foundation awarded a total of ... for pre-clinical research on potential new treatm...as awarded under the Foundation,s Therapeutics De...d in 2006, supports and bolsters industry-focused ...MJFF,s focus on ,de-risking, preclinical PD rese...
Breaking Medicine Technology:Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 3ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2TFAH Urges Congress to Override Presidents Veto of Labor HHS Appropriations 6377 1Escalon 28R 29 Reports First Quarter Fiscal 2008 Results 6375 1Escalon 28R 29 Reports First Quarter Fiscal 2008 Results 6375 2Escalon 28R 29 Reports First Quarter Fiscal 2008 Results 6375 3Escalon 28R 29 Reports First Quarter Fiscal 2008 Results 6375 4Escalon 28R 29 Reports First Quarter Fiscal 2008 Results 6375 5Escalon 28R 29 Reports First Quarter Fiscal 2008 Results 6375 6Escalon 28R 29 Reports First Quarter Fiscal 2008 Results 6375 7Stryker Corp 26 Physiotherapy Associates to Pay U S 2416 6 Million for Alleged False Claims to Federal Health Care Programs 6373 1Stryker Corp 26 Physiotherapy Associates to Pay U S 2416 6 Million for Alleged False Claims to Federal Health Care Programs 6373 2Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 6371 1Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 6371 2Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 6371 3Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 6371 4
... A Unique Viral Kinetics Profile, LAUSANNE, Switze...roup (Debiopharm), a global independent biopharmac...ious medical conditions,presented additional resu...ophilin (Cyp) inhibitor Debio 025 in HIV/HCV (hepa... presented at the 42nd,Annual Meeting of the Europ...
... LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abra... global biopharmaceutical,company, discussed resul...ence for chemotherapy induced angiogenesis and,rat...or Injectable,Suspension (paclitaxel protein-bound...nd)) with VEGF inhibitor drugs like,bevacizumab (A...
Other Medicine Technology:Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 2Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 3Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5
...oning System provides a versatile means of section... 3000 employs a vibrating blade principle which al...e creation of artifacts, the alteration of morphol...er deleterious effect inherent in freezing or embe...
...ic Tissue Sectioning System has maintained the rep...Researchers from around the globe have relied on t...h fixed tissue sectioning needs for over 20 years....Systems, the biological viability of the tissue is...
...oning System provides a versatile means of section... 3000 employs a vibrating blade principle which al...e creation of artifacts, the alteration of morphol...er deleterious effect inherent in freezing or embe...
The Vibratome comes standard with a square vice mounting device. These specimen blocks are utilized for mounting specimens and placing in the Vibratome holding vice. The blocks are annodized black
Medicine Products: